Other gene products with a direct therapeutic effect such as TRAIL [32] or interleukin-12 [33] or the simultaneous expression of different therapeutic gene products [34] have been preclinically tested using stem cell-based approaches and may be more effective while also expanding the so far highly limited therapeutic options in malignant glioma. The gene discussed is TNFSF10; the disease is malignant glioma.